Home > Documents in Process > Effect of Mobile Stroke Unit Dispatch on Process Parameters and Functional Outcomes in Patients With Acute Stroke: The B_PROUD-2.0 Study. > print

001     281789
005     20251017162656.0
024 7 _ |a 10.1212/WNL.0000000000214225
|2 doi
024 7 _ |a pmid:41100781
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
037 _ _ |a DZNE-2025-01182
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rohmann, Jessica L
|0 0000-0003-2420-5716
|b 0
245 _ _ |a Effect of Mobile Stroke Unit Dispatch on Process Parameters and Functional Outcomes in Patients With Acute Stroke: The B_PROUD-2.0 Study.
260 _ _ |a Philadelphia, Pa.
|c 2025
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760711042_15315
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Prehospital stroke management on mobile stroke units (MSUs) shortens time to IV thrombolysis (IVT) and improves functional outcomes. Because IVT effects are time-dependent, optimizing workflows and dispatch-related processes may enhance MSU benefits. The B_PROUD-2.0 study aimed to determine the effect of additional MSU dispatch on functional outcomes in acute stroke patients under optimized MSU organization and service delivery.In the nonrandomized, controlled B_PROUD-2.0 study (May 2019-April 2021) conducted in Berlin, Germany, MSUs were simultaneously dispatched with conventional care ambulances for suspected stroke emergency calls, whenever available. We compared outcomes and process parameters between dispatch groups (additional MSU dispatch vs conventional care only) among patients with cerebral ischemia with disabling neurologic symptoms and no contraindications to reperfusion treatments. We used data from the Berlin dispatch center and records from the B_SPATIAL registry, consisting of 15 Berlin hospitals with stroke units. We performed pooled analyses with the B_PROUD-1.0 primary population (February 2017-April 2021) and with an extended cohort that also included patients with reperfusion treatment contraindications. The primary and co-primary outcomes were 3-month modified Rankin Scale scores (0: no deficits to 6: death) and 3-tiered disability scale scores. Effect estimates for these outcomes were obtained from ordinal logistic regressions, adjusting for a priori selected covariates after multiple imputation for missing values.Coronavirus disease 2019 pandemic and limited funding hindered full implementation of procedural improvements. A total of 1,050 patients (mean age: 74 years, 46.7% female) were included in B_PROUD-2.0 (vs 1,500 planned). We found no statistically significant effect of MSU dispatch on primary (common odds ratio [cOR] 0.90, 95% CI 0.72-1.14) or co-primary (cOR 0.86, 95% CI 0.63-1.17) outcomes in B_PROUD-2.0, and higher odds of IVT ≤1 hour of dispatch in the MSU group (OR 10.15, 95% CI 7.10-14.51). In pooled B_PROUD-1.0+2.0 primary population analyses (N = 2,666, mean age: 73 years, 46.8% female), we found a beneficial effect on primary (cOR 0.80, 95% CI 0.67-0.96) and co-primary (cOR 0.79, 95% CI 0.64-0.97) outcomes. The average effect on all stroke/TIA patients in the extended cohort (N = 4,336, mean age 75 years, 47.6% female) was also favorable (primary cOR 0.85, 95% CI 0.75-0.95; co-primary cOR 0.86, 95% CI 0.75-0.99).While we did not observe statistically significant differences in functional outcomes in the underpowered B_PROUD-2.0 study, we found beneficial effects considering both B_PROUD study periods, also when including all stroke/TIA patients.ClinicalTrials.gov: NCT03931616. Registered: April 26, 2019. First patient enrolled: May 9, 2019.The B_PROUD-2.0 study provides Class III evidence that the addition of MSUs to conventional care ambulances did not improve functional outcomes at 3 months compared with conventional care ambulances alone in patients with acute ischemic stroke.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Mobile Health Units
|2 MeSH
650 _ 2 |a Stroke: therapy
|2 MeSH
650 _ 2 |a Thrombolytic Therapy
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Emergency Medical Services: methods
|2 MeSH
650 _ 2 |a Ambulances
|2 MeSH
650 _ 2 |a Time-to-Treatment
|2 MeSH
650 _ 2 |a Registries
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Emergency Medical Dispatch
|2 MeSH
650 _ 2 |a Berlin
|2 MeSH
650 _ 2 |a COVID-19
|2 MeSH
700 1 _ |a Piccininni, Marco
|0 0000-0002-1397-0060
|b 1
700 1 _ |a Ebinger, Martin
|0 0000-0002-5073-4665
|b 2
700 1 _ |a Wendt, Matthias
|b 3
700 1 _ |a Weber, Joachim E
|b 4
700 1 _ |a Schwabauer, Eugen
|b 5
700 1 _ |a Freitag, Erik
|b 6
700 1 _ |a Zuber, Martina
|b 7
700 1 _ |a Bernhardt, Lydia
|b 8
700 1 _ |a Lange, Julia
|b 9
700 1 _ |a Erdur, Hebun
|b 10
700 1 _ |a Behrens, Janina
|b 11
700 1 _ |a Ganeshan, Ramanan
|0 0000-0003-4043-1115
|b 12
700 1 _ |a Schlemm, Ludwig
|0 0000-0003-4165-2366
|b 13
700 1 _ |a Harmel, Peter
|b 14
700 1 _ |a Liman, Thomas G.
|0 P:(DE-2719)9000189
|b 15
|u dzne
700 1 _ |a Lorenz-Meyer, Irina
|b 16
700 1 _ |a Rohrpasser-Napierkowski, Ira
|b 17
700 1 _ |a Hille, Annegret
|b 18
700 1 _ |a Bohner, Georg
|b 19
700 1 _ |a Nabavi, Darius G
|b 20
700 1 _ |a Schmehl, Ingo
|b 21
700 1 _ |a Ekkernkamp, Axel
|b 22
700 1 _ |a Jungehulsing, Gerhard J
|b 23
700 1 _ |a Mackert, Bruno-Marcel
|b 24
700 1 _ |a Hartmann, Andreas
|b 25
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 26
700 1 _ |a Audebert, Heinrich J
|0 0000-0002-4785-0366
|b 27
773 _ _ |a 10.1212/WNL.0000000000214225
|g Vol. 105, no. 9, p. e214225
|0 PERI:(DE-600)1491874-2
|n 9
|p e214225
|t Neurology
|v 105
|y 2025
|x 0028-3878
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)9000189
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21